786
Views
17
CrossRef citations to date
0
Altmetric
Author's View

A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies

, , , , &
Article: e1022306 | Received 13 Jan 2015, Accepted 19 Feb 2015, Published online: 15 Jun 2015

Figures & data

Figure 1. Potential immune antitumor modes of action of IPH4102 in CTCL. Binding of IPH4102 to Fc receptor-bearing natural killer (NK) cells or macrophages leads to the targeting and elimination of KIR3DL2+ cutaneous T-cell lymphoma (CTCL) tumor cells by antibody-dependent cell cytotoxicity (ADCC) or/and antibody-dependent cell phagocytosis (ADCP). Because of the reciprocal relative ratios of NK cells to macrophages in the blood stream and skin, one can predominantly expect ADCC in the blood and ADCP in the dermis as immunologic mechanisms of tumor target elimination.

Figure 1. Potential immune antitumor modes of action of IPH4102 in CTCL. Binding of IPH4102 to Fc receptor-bearing natural killer (NK) cells or macrophages leads to the targeting and elimination of KIR3DL2+ cutaneous T-cell lymphoma (CTCL) tumor cells by antibody-dependent cell cytotoxicity (ADCC) or/and antibody-dependent cell phagocytosis (ADCP). Because of the reciprocal relative ratios of NK cells to macrophages in the blood stream and skin, one can predominantly expect ADCC in the blood and ADCP in the dermis as immunologic mechanisms of tumor target elimination.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.